MedTrace Logo

Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma

NCT02841332 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2016-12-20

No results posted yet for this study

Summary

The purpose of this study is to estimate the capacity of the multimodal imaging parameters measured at 15 days and 2 months of initiation of treatment with bevacizumab, to measure changes in clinical status (sensitivity to measure changes) in patients treated for recurrent glioblastoma.

Conditions

Interventions

DRUG

F-MISO

The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO). Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic.

OTHER

Cerebral magnetic resonance imagery

During the pre-therapeutic imagery session : * Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial ) * magnetic resonance imagery spectroscopy sequence * Perfusion magnetic resonance imagery sequence * Diffusion magnetic resonance imagery sequence

DRUG

Bevacizumab

Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)

OTHER

Clinical examination

During the examination, the following parameters will be checked : * Neurological examination * Corticotherapy prescribed * General status of patient (world health organization score) * Weight and height * Control of arterial pressure * Chirurgical and medical history * Concomitant treatment

Sponsors & Collaborators

  • University Hospital, Toulouse

    lead OTHER

Principal Investigators

  • Alexandra Benouaich-Amiel, MD · U H Toulouse

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2016-09-30
Completion
2016-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02841332 on ClinicalTrials.gov